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Abstract
Background: There are currently no large general population epidemiological studies of
Mycoplasma genitalium (MG), which include prevalence, risk factors, symptoms and co-
infection in men and women across a broad age range.
Methods: In 2010-–12, we conducted the third National Survey of Sexual Attitudes and
Lifestyles (Natsal-3), a probability sample survey in Britain. Urine from 4507 sexually-
experienced participants, aged 16–44 years, was tested for MG.
Results: MG prevalence was 1.2% [95% confidence interval (CI): 0.7–1.8%] in men and
1.3% (0.9–1.9%) in women. There were no positive MG tests in men aged 16–19, and
prevalence peaked at 2.1% (1.2–3.7%) in men aged 25–34 years. In women, prevalence
was highest in 16–19 year olds, at 2.4% (1.2–4.8%), and decreased with age. Men of Black
ethnicity were more likely to test positive for MG [adjusted odds ratio (AOR) 12.1; 95% CI:
3.7–39.4). For both men and women, MG was strongly associated with reporting sexual
risk behaviours (increasing number of total and new partners, and unsafe sex, in the past
year). Women with MG were more likely to report post-coital bleeding (AOR 5.8; 95%CI
1.4–23.3). However, the majority of men (94.4%), and over half of women (56.2%) with
MG did not report any sexually transmitted infection (STI) symptoms. Men with MG
were more likely to report previously diagnosed gonorrhoea, syphilis or non-specific ur-
ethritis, and women previous trichomoniasis.
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Original article
Conclusions: This study strengthens evidence that MG is an STI. MG was identified in
over 1% of the population, including in men with high-risk behaviours in older age
groups that are often not included in STI prevention measures.
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Introduction
There is growing evidence that Mycoplasma genitalium
(MG) is a cause of non-specific urethritis (NSU) in men, and
a putative cause of genital tract disease in women, although
its natural history and clinical sequelae remain unclear.1–3
Our knowledge of this organism, which was first isolated in
the 1980s, has been enhanced by the development of DNA
amplification assays which can now be used in clinical set-
tings and large-scale epidemiological studies. Guidelines for
MG testing, treatment and control procedures, both on an
individual clinical level and a population level, are needed.
These will evolve as the evidence base accumulates and com-
mercial testing for MG becomes more widely available.4,5
There are currently no data on the epidemiology of MG
in any general population sample that extends the age
range beyond 27 years and includes both men and women
(Table 1).6–10 Much of our current understanding of the
transmission dynamics of MG, including associations with
sexual behaviour, is derived from studies conducted in se-
lected populations, such as HIV-positive women,11 and is
limited to young people.6–10 These include settings such as
sexual health clinics, primary care, chlamydia screening
programmes and further education colleges.
Using data from Britain’s third National Survey of
Sexual Attitudes and Lifestyles (Natsal-3), we have previ-
ously described the epidemiology of Chlamydia trachoma-
tis (CT), Neisseria gonorrhoeae (GC), high-risk human
papillomavirus (HR-HPV) and HIV in the British popula-
tion and reported associations with sexual behaviour.12 In
this paper, we aimed to describe the epidemiology of MG
in British men and women aged 16–44 and explore its
characteristics as a potential STI (through combining
prevalence and behavioural data; comparison with other
known STIs; occurrence of co-infection; and reported
symptoms), to inform STI control strategies.
Methods
Participants and procedure
Natsal-3 was a stratified probability sample survey of
15 162 men and women aged 16–74 years in Britain
(England, Scotland and Wales), interviewed in 2010–12.
The overall response rate was 57.7% of all eligible
addresses, with 65.8% of potential respondents at eligible
addresses where contact was made agreeing to take part in
the survey (the cooperation rate). Participants were inter-
viewed using computer-assisted face-to-face and self-com-
pletion (CASI) questionnaires, which included questions on
participants’ sexual lifestyles, history of STIs and current
STI symptoms. Full details of Natsal-3 methods, including
power calculations, are described elsewhere.13,14
Urine collection
Following the interview, a sample of participants (all
16–17-year-olds and a sample of 18–44-year-olds who re-
ported at least one sexual partner, ever) were invited to
Key Messages
• This study strengthens evidence that MG is an STI: there were strong associations with risky sexual behaviours, with
behavioural risk factors similar to those in other known STIs, and no infections were detected in those reporting no
previous sexual experience.
• Given the uncertainty on the natural history and clinical implications of infection, especially in women, here we report
that although asymptomatic infection was common, we found a strong association with post-coital bleeding in
women. Thus in addition to MG being an STI, it can be an STD.
• MG was identified in over 1% of the population aged 16–44, and among men was most prevalent in 25–34-year-olds,
who would not be included in STI prevention measures aimed at young people.
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provide a urine specimen. Sample size calculations assumed
an estimated prevalence of 1.5% for MG, which would give
at least 80% power to estimate the prevalence within 0.6%
in each gender and univariate associations. Of the 8047 re-
spondents aged 16–44 years who reported at least one sex-
ual partner, ever, 4828 (60.0%) agreed to provide a sample
to be tested for a range of infections.12 Urine test results for
MG were available on 4507 samples. We also obtained
urine samples from 205 of the 406 respondents aged 16–17
years who had reported never having had vaginal, anal or
oral sex, and we have an MG result on 189 of these partici-
pants. Urine was collected using the FirstBurst device, which
collects the first 4–5 ml of voided urine, yielding a higher
CT organism load than the regular urine cup,15 which is
likely to also increase detection of MG.
Laboratory methods
Samples were posted to Public Health England (PHE) for
testing. Details of urine sample preparation, testing for CT,
GC, HPV and HIV, and quality assurance, are available
elsewhere.13,14 For MG, urine specimens were tested using
an in-house real-time polymerase chain reaction (PCR)
assay which targets the Mycoplasma genitalium adhesin
protein (MgPa) gene,16 with positive or equivocal results
confirmed using the Aptima Mycoplasma genitalium test
(RUO, Hologic Inc., San Diego, USA).17
Statistical analysis
All analyses were done in Stata v13, accounting for stratifi-
cation, clustering and weighting of the sample.13,14 In
order to minimize non-participation bias, the Natsal-3
data were weighted in two stages. The first stage corrects
for participants’ unequal probabilities of selection for in-
clusion in the sample, with weights applied which were in-
versely proportional to the selection probabilities for the
numbers of households and adults within the eligible age
range at each selected address. The second stage adjusts for
differential non-response by comparing the age, gender
Table 1. Community-based studies of Mycoplasma genitalium
Setting Study participants Age Sample
size
Specimen Prevalence Risk factors Reference
MEN
US National Longitudinal
Study of Adolescent
Health (Add Health)
18–27 1218 Urine 1.1% (0.5–2.4) (Men and women combined):
ever lived with a partner, Black
ethnicity, ever had vaginal
intercourse,  2 lifetime partners,
 1 partner in the past year,
condom use at last vaginal
intercourse
Manhart
et al.7
Denmark Chlamydia Screening
Programme
21–23 731 Urine 1.1% (0.3–1.9) Younger age at first sex, > 6 part-
ners in the past year, > 3 partners
in the past 6 months
Andersen
et al.6
WOMEN
US National Longitudinal
Study of Adolescent
Health (Add Health)
18–27 1714 Urine 0.8% (0.4–1.6) See above Manhart
et al.7
London Chlamydia Screening
Programme
15–24 1424 Urine 1.0% (0.6–1.7) (For all specimen types combined):
Black ethnicity, > 1 partner in the
past year
Svenstrup
et al.9
London Chlamydia Screening
Programme
15–24 1017 Cervical/ vaginal
swab
4.1% (3.0–5.5) See above Svenstrup
et al.9
Denmark Chlamydia Screening
Programme
21–23 921 Vulvo-vaginal
swab
2.3% (1.3–3.2) > 10 lifetime partners,  2 partners
in the past year, shorter duration
of steady relationship, partner
with symptoms
Andersen
et al.6
Australia General practice 15–25 1116 Vulvo-vaginal
swab
1.6% (0.7–2.6) Indigenous status,  2 partners in
the past year,  3 partners in the
past year without condoms
Walker
et al.10
London Students (POPI trial) 15–27 2378 Vulvo-vaginal
swab
3.3% (2.6–4.1)  2 partners in the past year,  18
years, Black ethnicity, smoking
Oakeshott
et al.8
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and regional profile of participants with 2011 Census data.
The final weighted sample closely matches the distribution
of demographic characteristics in the 2011 Census. In
order to reduce bias in the urine results, we included an
additional ‘urine weight’, which is the product of a weight
that corrects for differential urine sample response after al-
ready weighting for different selection probabilities.13,14
The urine non-response weight is the inverse of the pre-
dicted probability of urine response from a logistic regres-
sion model, which is based on forwards stepwise model
selection conducted separately among men and women,
and with age included a priori. Differences in the provision
of a urine sample were small. In general, those who were
younger, who reported same-sex experience and higher-
risk behaviours, such as more unprotected partners, were
more likely to provide a urine sample.
We present weighted prevalence estimates of MG in men
and women, by age group, with 95% confidence intervals
(CIs), in participants aged 16–44 years who reported at least
one sexual partner, ever. We examined the relationships be-
tween MG and demographic and behavioural variables
using logistic regression and present crude and adjusted
odds ratios (ORs, AORs) and compared these with risk fac-
tors for other STIs (CT and HR-HPV), that we have previ-
ously reported.12 Multivariable analyses adjusted for two
demographic variables [age and area-level deprivation
(IMD)]18 and one behavioural factor (number of sexual
partners in the past year). Analyses of number of new part-
ners in the past year and unsafe sex (defined as sex with two
or more partners in the past year and never used condoms
in the past year), were only adjusted for age and IMD, due
to collinearity with total number of partners in the past
year. We examined the association between MG and re-
ported previous STI diagnoses, current co-infection, and STI
symptoms over the past month, and present AORs. To pro-
vide further evidence about whether MG is sexually trans-
mitted, we report whether MG was detected in urine in the
16–17 year olds who had not had sex, and in those report-
ing at least one partner, ever, but only having oral sex.
Ethics
We obtained ethical approval from Oxfordshire Research
Ethics Committee A (No. 09/H0604/27). Participants gave
written informed consent to anonymized testing without
the return of results, the ethical rationale for which has
been previously described.19 To avoid potential deductive
disclosure to others in the household, urine was requested
from all participants aged 16–17 years irrespective of sex-
ual experience. All participants were provided with infor-
mation on where to obtain free diagnostic STI/HIV testing
and sexual health advice.
Results
Prevalence
We detected MG in urine from 24 sexually experienced
men and 48 sexually experienced women, giving a
weighted prevalence of 1.2% (95% CI: 0.7–1.8%) in men
and 1.3% (0.9–1.9%) in women aged 16–44 (Table 2)
[combined weighted prevalence in men and women aged
16–44 was 1.2% (0.9–1.7)]. There were no positive MG
tests in men aged 16–19, and prevalence peaked at 2.1% in
men aged 25–34 years. In contrast, in women prevalence
was highest in 16–19-year-olds, at 2.4%, and decreased
with age. The prevalences in those aged 16–24 years were
0.4% (0.1–1.1%) in men and 1.7% (1.1–2.6%) in women
[combined weighted prevalence in men and women aged
16–24 was 1.0% (0.7–1.5)]. Over 90% of MG in men
[90.6% (75.8–96.8%)] and two-thirds of MG in women
[66.5% (50.3–79.5%)] was in those aged 25–44 years.
Risk factors
Table 2 shows demographic risk factors for MG. Men of
Black ethnicity (AOR 12.05; 95% CI 3.68–39.44) and
those living in the most deprived areas (AOR 3.66; 1.27–
10.47) were more likely to test positive for MG. When
additionally adjusting for ethnicity, the association be-
tween MG positivity and area-level deprivation in men
reduced to an AOR of 2.83, although this was no longer
statistically significant (AOR adjusted for age, number of
partners in the past year and ethnicity: 2.83;0.87–9.21).
We did not find any significant associations with socio-
demographic factors in women. For both men and women,
MG was strongly associated with reporting a range of sex-
ual risk behaviours (increasing number of total and new
partners, and unsafe sex, in the past year) (Table 3), al-
though the magnitudes of the AORs were greater in men
than in women. Women, but not men, reporting ever hav-
ing same-sex experience were more likely to test MG-posi-
tive (OR 2.80; 1.09–7.22), and this association remained
after adjusting for age, IMD and number of partners, albeit
not statistically significantly (AOR 2.10; 0.72–6.07).
Figure 1 compares AORs for a number of risk factors
for MG, CT and HR-HPV by gender. Apart from age, and
in women ever having same-sex experience, the direction
and magnitude of risks were broadly similar for MG, CT
and HR-HPV.
Previous STI diagnoses and current co-infection
Men with MG were more likely to report having been
diagnosed with gonorrhoea, syphilis and/or NSU/NGU
(non-gonococcal urethritis) in the past 5 years than those
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MG-negative, with women being more likely to report a
diagnosis of trichomoniasis, although numbers are small
(Table 4). Men and women who were MG-positive were
more likely to have HR-HPV, and any HPV, detected in
urine than those MG-negative. Only two respondents (one
man and one woman) had both MG and CT detected in
urine. One man had MG and GC co-infection.
Symptoms
The majority of men [94.4% (79.4–98.7%)] and over
half [56.2% (37.5–73.3%)] of women with MG did not
report any STI symptoms in the past month. In men there
were no associations between reported STI symptoms
and MG positivity. Women who tested positive for MG
were more likely to report STI symptoms in the
past month than those who tested negative (Table 5)
(43.8% vs 25.7%; OR 2.26; 1.05–4.84) and this
association remained after adjusting for CT, GC or HR-
HPV co-infection (AOR 2.19; 1.00–4.78; P¼ 0.05).
When looking at specific symptoms, women with MG
were significantly more likely to report having experi-
enced bleeding after sex (OR 6.15; 1.64–23.09; AOR ad-
justed for age, current CT, GC or HR-HPV 5.78 (1.43–
23.34); P¼ 0.014).
MG in participants who were not sexually-
experienced or only reported oral sex
MG test results were available from 89 men and 100
women aged 16–17 years who reported not having had
sex, all of which were negative. There were also no positive
MG tests in sexually experienced participants aged 16–44
years who only reported having had oral sex (n¼ 20 men
and 22 women).
Table 4. Associations between MG in urine, self-reported STI diagnoses in the past 5 years and CT and HR-HPV in urine, by
gender
MG-negative MG-positive OR 95% CI P-value
Men
Self-reported previous diagnoses: % (95% CI)
Diagnosed with an STI in past 5 yearsa 5.5% [4.6%,6.7%] 10.4% [3.5%,26.8%] 1.97 (0.61–6.38) 0.257
Chlamydia 3.6% [2.8%,4.6%] 10.4% [3.5%,26.8%] 3.09 (0.95–10.05) 0.060
Gonorrhoea 0.3% [0.1%,0.6%] 3.6% [0.8%,13.9%] 12.88 (2.43–68.19) 0.003
Genital warts 1.3% [0.8%,1.9%] 3.6% [0.8%,13.9%] 2.88 (0.61–13.49) 0.179
Syphilis 0.2% [0.1%,0.6%] 2.0% [0.3%,13.4%] 10.98 (1.06–113.33) 0.044
Trichomoniasis 0.0% – 0.0% – – – –
Herpes 0.4% [0.2%,0.8%] 0.0% – – – –
NSU/NGU 0.8% [0.5%,1.2%] 3.6% [0.8%,13.9%] 4.88 (1.01–23.52) 0.048
Urine prevalence: % (95% CI)
Chlamydia trachomatis in urine 1.1% [0.8%,1.6%] 3.8% [0.5%,22.9%] 3.69 (0.47–28.85) 0.182
HR-HPV in urine 8.1% [6.5%,10.1%] 35.0% [16.2%,60.0%] 6.10 (2.13–17.45) <0.001
HPV (any type) in urine) 16.0% [13.9%,18.3%] 40.6% [20.6%,64.3%] 3.60 (1.35–9.60) 0.006
Women
Self-reported previous diagnoses: % (95% CI)
Diagnosed with an STI in past 5 yearsa 6.0% [5.1%,7.1%] 8.5% [3.8%,18.0%] 1.45 (0.61–3.43) 0.397
Chlamydia 4.1% [3.5%,4.9%] 3.2% [1.0%,9.9%] 0.76 (0.23–2.56) 0.660
Gonorrhoea 0.4% [0.2%,0.8%] 0.0% – – – –
Genital warts 1.4% [1.0%,1.9%] 4.2% [1.3%,13.0%] 3.09 (0.88–10.83) 0.077
Syphilis <0.1% [0.0%,0.1%] 0.0% – – – –
Trichomoniasis 0.1% [0.0%,0.2%] 1.1% [0.2%,7.7%] 14.70 (1.53–140.88) 0.020
Herpes 0.9% [0.6%,1.4%] 1.3% [0.2%,9.1%] 1.53 (0.21–11.00) 0.672
Urine prevalence: % (95% CI)
Chlamydia trachomatis in urine 1.5% [1.1%,2.0%] 1.2% [0.2%,8.2%] 0.82 (0.11–6.27) 0.848
HR-HPV in urine 15.6% [14.0%,17.2%] 41.0% [25.4%,58.6%] 3.77 (1.82–7.78) <0.001
HPV (any type) in urine) 30.2% [28.1%,32.5%] 68.3% [47.8%,83.5%] 4.96 (2.11–11.68) <0.001
Denominator (unweighted, weighted)
Men (1833, 2202) (24, 26)
Women (2568, 2201) (48, 29)
Denominator is participants aged 16–44 who reported at least one partner, with an MG test result. MG-negative is the reference category.
aDiagnosed with chlamydia, gonorrhoea, genital warts, syphilis, trichomoniasis, herpes in the past 5 years.
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Discussion
This population-based study, which includes men and
women across a broad age range, found an overall preva-
lence of MG in urine from sexually-experienced people of
1.2% in men and 1.3% in women, and associations with a
range of sexual behaviours and with other STIs.
There are different opinions on whether MG is a puta-
tive or confirmed STI. M. genitalium has been shown to
be sexually transmissible, as evidenced by partner studies
which demonstrate concurrent infection with concordant
strain types.20,21 The cumulative epidemiological evi-
dence in the literature is increasingly supporting the view
that it is an STI (Table 1). This study adds to that evi-
dence and gives further insights into the transmission dy-
namics of this infection. We detected no MG in those
who had not had sex, or who only reported oral sex, al-
though we may not expect to detect positives since: we
found no MG in sexually experienced 16–19-year-old
men; numbers are small; and the overall prevalence is
low. Similarly, the study in US adolescents reported much
higher prevalence in those reporting ever having had vagi-
nal intercourse compared with those who had not.7We do
show that, on a population level, MG was associated with
a range of behavioural risk factors, as others have
found,6,7,9,10 including increasing number of partners and
unsafe sex. For example, prevalence was much higher in
those reporting more partners (5.2% in men and 3.1% in
women reporting four or more partners in the past year).
The high ORs suggest that MG may be associated with
same-sex experience in women, but not men, although
confidence intervals are wide. All of the women reporting
same-sex experience reported also having had sex with
men, however one had only had sex with women in the
past 5 years. The one man with MG reported having sex
exclusively with men for the past 5 years. The association
between same-sex sexual practices and MG may be better
studied in specific populations, such as clinic attendees,
than in national surveys.
Table 5. Reported STI symptoms in the past month, among those with and without MGin urine, and gender
MG-negative MG-positive OR P-value AOR P-value
Men
Any STI symptom:
% (95% CI)
7.3% [6.1%,8.9%] 5.6% [1.3%,20.6%] 0.75 (0.17–3.35) 0.706 0.68 (0.15–3.09) 0.619
Pain, burning or stinging
passing urine
2.3% [1.7%,3.2%] 2.6% [0.4%,16.7%] 1.13 (0.15–8.69) 0.909 0.80 (0.10–6.23) 0.813
More frequent urination 2.5% [1.8%,3.6%] 0.0% – – – – – –
Genital warts/lumps 0.8% [0.4%,1.5%] 0.0% – – – – – –
Genital ulcers/sores 0.2% [0.1%,0.6%] 0.0% – – – – – –
Penile discharge 0.3% [0.2%,0.7%] 0.0% – – – – – –
Painful testicles 2.8% [2.1%,3.7%] 3.0% [0.4%,19.0%] 1.09 (0.14–8.48) 0.936 1.43 (0.18–11.10) 0.731
Women
Any STI symptom:
% (95% CI)
25.7% [23.7%,27.7%] 43.8% [26.7%,62.5%] 2.26 (1.05–4.84) 0.037 2.15 (0.92–5.00) 0.077
Pain, burning or stinging
passing urine
7.8% [6.6%,9.0%] 7.8% [1.1%,38.2%] 1.00 (0.14–7.40) 0.999 0.87 (0.10–7.41) 0.900
More frequent urination 5.2% [4.3%,6.3%] 8.6% [1.5%,36.3%] 1.72 (0.28–10.49) 0.558 1.49 (0.22–10.15) 0.682
Genital warts/lumps 0.8% [0.5%,1.4%] 0.0% – – – – – –
Genital ulcers/sores 0.7% [0.4%,1.3%] 1.8% [0.3%,12.0%] 2.73 (0.34–22.18) 0.347 2.13 (0.27–16.76) 0.470
Abnormal vaginal discharge 4.0% [3.3%,4.9%] 0.9% [0.1%,6.3%] 0.22 (0.03–1.61) 0.135 0.18 (0.03–1.35) 0.096
Odorous vaginal discharge 4.0% [3.2%,5.0%] 5.0% [1.5%,15.7%] 1.27 (0.35–4.54) 0.718 1.11 (0.32–3.78) 0.871
Vaginal pain during sex 6.7% [5.6%,8.1%] 9.1% [2.7%,26.7%] 1.39 (0.38–5.12) 0.618 1.29 (0.34–4.83) 0.706
Bleeding between periods 4.5% [3.7%,5.5%] 7.1% [1.6%,25.9%] 1.62 (0.35–7.51) 0.541 1.73 (0.36–8.39) 0.493
Bleeding after sex 2.7% [2.0%,3.5%] 14.4% [4.4%,38.2%] 6.15 (1.64–23.09) 0.007 5.78 (1.43–23.34) 0.014
Lower abdominal /
pelvic pain
6.3% [5.2%,7.7%] 10.8% [3.7%,27.6%] 1.80 (0.57–5.72) 0.318 1.65 (0.53–5.17) 0.390
Denominator (unweighted, weighted)
Men (1849, 2222) (24, 26)
Women (2578, 2215) (48, 29)
Denominator is those aged 16–44 who reported at least one sexual partner, ever. MG-negative is the reference category.
AOR, adjusted odds ratio, adjusted for chlamydia, gonorrhoea, HR-HPV infection, and age.
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The prevalence estimates and risk factors identified in
this study are consistent with those obtained from the
other community-based studies, such as those reported
from urine from young people in the US National
Longitudinal Study of Adolescent Health7 and from a re-
cent London-based study in women aged 15–24 undergo-
ing population-based chlamydia screening9 (Table 1).
Nevertheless, there are potential biases in cross-sectional
surveys with complex sampling designs, and other
methodological challenges in sexual behaviour survey re-
search,22 which will influence behavioural and STI preva-
lence estimates. It is difficult to assess survey non-response
bias or how it impacts on prevalence estimates, given that
little is known about non-responders. A recent interna-
tional review found that surveys with lower response rates
tended to produce higher chlamydia prevalence estimates.
However, there was no evidence that this was the case for
studies such as Natsal, with nationally representative sam-
ples.23 After weighting the Natsal-3 data to the British
population Census data on age, sex and region, we found
the profile of our sample was broadly comparable to the
population in terms of ethnicity, marital status and self-re-
ported general health.13,14 In contrast to non-participation
bias to the survey, bias from non-provision of biological
samples as a part of larger behavioural surveys can be bet-
ter assessed, because demographic and behavioural data
are known regarding those who take part in the survey but
do not provide samples. We used these data to minimize
the potential bias from sample non-provision by generating
additional urine weighting.
The absolute prevalences in women are likely to be an
underestimate, as MG is less likely to be detected from
urine than vaginal swabs,9,24 although in our study this
may be partially rectified by using the FirstBurst collection
system. Natsal-3, in common with other studies using
urine,6,7 is able to determine relative prevalences and asso-
ciations with risk factors, other STIs and symptoms. The
study had sufficient power to estimate prevalence and uni-
variate associations. We present multivariable analyses
that are only adjusted for a limited number of demographic
and behavioural variables, and recognize that these AORs,
given their wide confidence intervals, need to be inter-
preted with caution.
However, we found that the overall prevalence masks
the heterogeneityof risk in the population, according to
demographic and behavioural factors. For example, in
men prevalence of MG was highest at 2.1% in those aged
25–34, whereas in women it peaked at 2.4% in those aged
16–19 years. Comparison of the epidemiology of MG in
men and women, and with other STIs, may provide in-
sights into the broader epidemiology, drivers of transmis-
sion and appropriate interventions. Nevertheless, most
studies to date have either been limited to women8–10 or
have combined analyses for men and women.7 We found
that the magnitudes of associations between MG and
socio-demographic and behavioural variables were greater
in men than women. In women MG was more evenly dis-
tributed, and others have reported (based on small num-
bers of women) that MG may circulate in sexual networks
different from those of CT or GC.10,25 It has been sug-
gested that MG in women may require broad-based strat-
egies for prevention since it seems that high rates of
partner change are not necessarily required to sustain
transmission.25 In contrast, we identified MG in men with
high-risk behaviours, who had a history of GC, syphilis
and NSU, which suggests that a control strategy that in-
cludes targeting this core group would be needed. The dif-
ferent findings in men and women may be due to chance,
given the low prevalence. They may also reflect differences
in age mixing, as men on average have partners younger
than themselves.26 It is also possible, in a population-based
survey, to have missed the women with highest risk behav-
iours or another ‘bridging population’.
The results from this study also generate a number of
hypotheses. In addition to social and behavioural factors
such as age and ethnic mixing, the transmission dynamics
and natural history may differ in men and women. This
may reflect biological and host factors that result in differ-
ences in the risk of infection following exposure, duration
of infectiousness, development of symptoms, likelihood of
persistence, rates of clearance and the role of reinfection.
Furthermore, comorbidity with and treatment for other
STIs may influence both the clinical course of MG infec-
tion and the development of drug resistance. The detailed
sexual behaviour data collected in Natsal-3, combined
with these MG results, provide parameter estimates for
mathematical models that explore the transmission dy-
namics of this infection.
We found a strong association with detection of MG
and Black ethnicity in men (OR 17.6), which remained
after adjusting for age, IMD and number of partners in the
past year (AOR 12.1). In addition to social and behav-
ioural factors that result in higher risk in this group, there
may be ethnic differences in innate immunity27 or in the
vaginal microbiome,28 which may influence the risk of ac-
quisition or persistence of infection. This finding is consist-
ent with those reported from other studies7,9,25 and may be
one explanation for the higher reported prevalence and in-
cidence of MG in the POPI trial in London students with a
high proportion of participants of Black ethnicity.8
Furthermore, surveillance data for England show high
rates of STI diagnoses in persons of Black ethnicity.29 As
ethnicity is a predictor of Trichomonas vaginalis infec-
tion,25 this may partly explain why we observed an
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association between MG and a history of trichomoniasis in
women. A better understanding of sexual mixing patterns
would inform whether intensified STI prevention and
treatment interventions, including enabling access to ser-
vices, may be warranted in those of Black ethnicity.
We found that the risk factors for MG were broadly
similar to those for two known STIs, CT and HR-HPV.
Men and women who were MG-positive were more likely
to have HR-HPV and any HPV detected in urine than
those who were MG-negative, which may be due to HR-
HPV being a proxy measure for riskier sexual behaviour.12
We found little MG/CT co-infection and the prevalence of
CT was not significantly different in those with and with-
out MG, as reported elsewhere.6,7,9 However, the power
to detect a significant association between MG and CT
was limited since the prevalences are low. The magnitudes
of the ORs suggest that men with MG are more likely to
have current or to report previous CT, but not women, al-
though again confidence intervals are wide and the associ-
ation was not significant.
This study provides insights for the testing and control
of MG infection, which need to be considered as part of
the emerging evidence base. Other study designs are better
placed to look at natural history of infection with M. geni-
talium and its sequelae. However, in order to ascertain
whether in addition to it being an STI it is an STD (i.e.
causes disease), our findings on symptoms are informative.
Women who tested positive for MG were more likely to re-
port symptoms than those who tested negative; however,
over half (56.2%) of women with MG did not report any
STI symptoms. Of note is that women with MG were more
likely (OR 6.2) to report post-coital bleeding, which may
result from cervical friability or cervicitis,30 and this strong
association remained after adjusting for age and co-infec-
tion. We did not, however, find that women with MG
were more likely to report other symptoms that are usually
associated with pelvic inflammatory disease, such as pelvic
pain, abnormal vaginal discharge or dyspareunia. Over
90% of men with MG did not report any STI symptoms
and men with MG were not more likely to report current
symptoms than those who tested negative, although they
were more likely to report a previous diagnosis of NSU
(OR 4.9). These findings suggest that only testing men
who are currently symptomatic would miss the vast major-
ity of infections. An understanding of the clinical implica-
tions of infection, together with information on resistance
patterns to guide antibiotic choice, will inform recommen-
dations on how to manage infection in symptomatic pa-
tients or in those who present to health services.4,5
There is the possibility that with rapidly-evolving diag-
nostic technologies, which include testing for multiple or-
ganisms on a single specimen (e.g. triple CT/GC/MG
assays), testing for MG becomes the default both in clinical
care and population screening. However, testing in settings
with low prevalence are more likely to have low positive
predictive values with false-positive results.31The overall
prevalence of MG in those aged 16–44 years is similar to
the prevalence of chlamydia in this population (1.1% in
men and 1.5% in women).12 However, there are differ-
ences in the age- and sex-specific prevalences of these two
infections which have important implications for control
strategies. The prevalences of MG and CT in those aged
16–24 years were 0.4% and 2.3% in men and 1.7% and
3.1% in women, respectively. Our data show that a hypo-
thetical MG screening programme targeting people aged
16–24 years (such as the National Chlamydia Screening
Programme) would only identify 1 in 10 men and 1 in 3
women with MG, as the majority of MG-positive men and
women were in the 25–44 year age group. General STI pre-
vention measures that promote a reduction in risk behav-
iour (e.g. increased condom use) are likely to impact on all
STIs, including MG. Further research in clinical and com-
munity-based settings, including those that explore sexual
networks, the molecular epidemiology of MG, age mixing
and other partnership factors across a range of STIs, will
elucidate the transmission dynamics of MG. This will in-
form the development of any further control strategies, if
these are deemed appropriate and cost-effective.
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